Canaan X L.p. - Net Worth and Insider Trading
Canaan X L.p. Net Worth
The estimated net worth of Canaan X L.p. is at least $158 Million dollars as of 2024-04-25. Canaan X L.p. is the 10% Owner of IDEAYA Biosciences Inc and owns about 2,660,713 shares of IDEAYA Biosciences Inc (IDYA) stock worth over $102 Million. Canaan X L.p. is the 10% Owner of Protagonist Therapeutics Inc and owns about 2,116,552 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $53 Million. Canaan X L.p. is also the 10% Owner of NextCure Inc and owns about 2,254,442 shares of NextCure Inc (NXTC) stock worth over $3 Million. Besides these, Canaan X L.p. also holds Iterum Therapeutics PLC (ITRM) . Details can be seen in Canaan X L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Canaan X L.p. has not made any transactions after 2019-05-28 and currently still holds the listed stock(s).
Transaction Summary of Canaan X L.p.
Canaan X L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Canaan X L.p. owns 5 companies in total, including Iterum Therapeutics PLC (ITRM) , IDEAYA Biosciences Inc (IDYA) , and NextCure Inc (NXTC) among others .
Click here to see the complete history of Canaan X L.p.’s form 4 insider trades.
Insider Ownership Summary of Canaan X L.p.
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ITRM | Iterum Therapeutics PLC | 2020-01-21 | director & 10 percent owner |
IDYA | IDEAYA Biosciences Inc | 2019-05-28 | 10 percent owner |
NXTC | NextCure Inc | 2019-05-13 | 10 percent owner |
PTGX | Protagonist Therapeutics Inc | 2018-05-17 | 10 percent owner |
ASTR | Astra Space Inc | 2021-06-30 | 10 percent owner |
Canaan X L.p. Latest Holdings Summary
Canaan X L.p. currently owns a total of 4 stocks. Among these stocks, Canaan X L.p. owns 2,660,713 shares of IDEAYA Biosciences Inc (IDYA) as of May 28, 2019, with a value of $102 Million and a weighting of 64.65%. Canaan X L.p. owns 2,116,552 shares of Protagonist Therapeutics Inc (PTGX) as of May 17, 2018, with a value of $53 Million and a weighting of 33.3%. Canaan X L.p. also owns 2,254,442 shares of NextCure Inc (NXTC) as of May 13, 2019, with a value of $3 Million and a weighting of 1.94%. The other 1 stocks Iterum Therapeutics PLC (ITRM) have a combined weighting of 0.11% among all his current holdings.
Latest Holdings of Canaan X L.p.
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
IDYA | IDEAYA Biosciences Inc | 2019-05-28 | 2,660,713 | 38.44 | 102,277,808 |
PTGX | Protagonist Therapeutics Inc | 2018-05-17 | 2,116,552 | 24.89 | 52,680,979 |
NXTC | NextCure Inc | 2019-05-13 | 2,254,442 | 1.36 | 3,066,041 |
ITRM | Iterum Therapeutics PLC | 2018-05-30 | 115,545 | 1.54 | 177,939 |
Holding Weightings of Canaan X L.p.
Canaan X L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Canaan X L.p. has made a total of 1 transactions in IDEAYA Biosciences Inc (IDYA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in IDEAYA Biosciences Inc is the acquisition of 400,000 shares on May 28, 2019, which cost Canaan X L.p. around $4 Million.
According to the SEC Form 4 filings, Canaan X L.p. has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the sale of 38,968 shares on May 17, 2018, which brought Canaan X L.p. around $237,315.
According to the SEC Form 4 filings, Canaan X L.p. has made a total of 1 transactions in NextCure Inc (NXTC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in NextCure Inc is the acquisition of 50,000 shares on May 13, 2019, which cost Canaan X L.p. around $750,000.
More details on Canaan X L.p.'s insider transactions can be found in the Insider Trading History of Canaan X L.p. table.Insider Trading History of Canaan X L.p.
- 1
Canaan X L.p. Trading Performance
GuruFocus tracks the stock performance after each of Canaan X L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Canaan X L.p. is 20.83%. GuruFocus also compares Canaan X L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Canaan X L.p. within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Canaan X L.p.'s insider trading performs compared to the benchmark.
Performance of Canaan X L.p.
Average Return
4.11%
Outperforming Transactions
50%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | -4.86 | 20.83 | 10.84 | 4.11 | -13.75 | -24.87 |
Relative Return to S&P 500(%) | -6.31 | 17.44 | 2.93 | -1.91 | -29.57 | -37.92 |
Canaan X L.p. Ownership Network
Ownership Network List of Canaan X L.p.
Ownership Network Relation of Canaan X L.p.
Canaan X L.p. Owned Company Details
What does Iterum Therapeutics PLC do?
Who are the key executives at Iterum Therapeutics PLC?
Canaan X L.p. is the director & 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .
Iterum Therapeutics PLC (ITRM) Insider Trades Summary
Over the past 18 months, Canaan X L.p. made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , a net purchase of 10,000 shares made by Fishman Corey N. , and a net sale of 3,365 shares made by Sailaja Puttagunta .
In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,365 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 61,635 shares.
Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Iterum Therapeutics PLC Insider Transactions
Canaan X L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Canaan X L.p.. You might contact Canaan X L.p. via mailing address: 2765 Sand Hill Rd, Menlo Park Ca 94025.